|
KG-1a
|
> 100 µg/mL
|
MTT assay
|
Download PDF
|
|
THP-1
|
6.34 μM
|
CCK-8 assay
|
Download PDF
|
|
U937
|
13.15 μM
|
CCK-8 assay
|
Download PDF
|
|
THP-1/R
|
36.01 μM
|
CCK-8 assay
|
Download PDF
|
|
U937/R
|
90.40 μM
|
CCK-8 assay
|
Download PDF
|
|
THP-1 (EV1)
|
8.22 μM
|
CCK-8 assay
|
Download PDF
|
|
THP-1 (sh-S100A4)
|
4.647 μM
|
CCK-8 assay
|
Download PDF
|
|
THP-1 (EV2)
|
7.361 μM
|
CCK-8 assay
|
Download PDF
|
|
U937 (EV1)
|
16.67 μM
|
CCK-8 assay
|
Download PDF
|
|
U937 (LV-S100A4)
|
36.26 μM
|
CCK-8 assay
|
Download PDF
|
|
U937 (sh-S100A4)
|
5.665 μM
|
CCK-8 assay
|
Download PDF
|
|
U937 (EV2)
|
16.31 μM
|
CCK-8 assay
|
Download PDF
|
|
MV4-11
|
10.783 μM
|
CCK-8 assay, dose-response curve
|
PMC12152671
|
|
OCI-AML3
|
1.87 µM
|
Cytarabine dose-response assays, apoptosis measured with Annexin V after 72 h, sigmoidal dose–response curves used to calculate LC50 values.
|
Download PDF
|
|
KASUMI-1
|
100 nM
|
MTT assay
|
Download PDF
|
|
Sem cells
|
80.8 nM
|
quantification of cells positive for amine-reactive dyes using flow cytometry
|
PMC11609812
|
|
Sem IKZF1-/- cells
|
155.8 nM
|
quantification of cells positive for amine-reactive dyes using flow cytometry
|
PMC11609812
|
|
WEHI-3
|
368.6 nM
|
MTS technique (CellTiter 96®AQueousOne Solution Cell Proliferation Assay)
|
Download PDF
|
|
HL-60
|
14.24 µM
|
MTT test
|
Download PDF
|
|
KG-1
|
18.21 µM
|
MTT test
|
Download PDF
|
|
PBMC
|
11.48 µM
|
MTT test
|
Download PDF
|
|
BMMC
|
10.29 µM
|
MTT test
|
Download PDF
|
|
MOLM13
|
4.79 µmol/L
|
Cell viability assay
|
Download PDF
|
|
MOLM13/R
|
>1000 µmol/L
|
Cell viability assay
|
Download PDF
|
|
KG-1 (NRASWT)
|
0.53 µM (with DUSP1 siRNA), 0.67 µM (control)
|
MTT assay
|
PMC10594969
|
|
KG-1 (NRASG13D)
|
0.39 µM (with DUSP1 siRNA), 0.69 µM (control)
|
MTT assay
|
PMC10594969
|
|
MOLM-13 (NRASWT)
|
0.59 µM (with DUSP1 siRNA), 0.61 µM (control)
|
MTT assay
|
PMC10594969
|
|
MOLM-13 (NRASG13D)
|
0.43 µM (with DUSP1 siRNA), 0.63 µM (control)
|
MTT assay
|
PMC10594969
|
|
MA-Cas9 cells
|
40 nM
|
CRISPR-Cas9 screen (dose used for screen)
|
PMC11497402
|
|
MA cells
|
sgCtrl: 0.188 PM; sgHerc1#1: 0.045 PM; sgHerc1#2: 0.064 PM
|
CTG Luminescent Cell Viability Assay
|
PMC11497402
|
|
HM cells
|
sgCtrl: 0.108 PM; sg1: 0.065 PM; sg2: 0.066 PM
|
CTG Luminescent Cell Viability Assay
|
PMC11497402
|
|
HEL
|
60.2 nM
|
MTT-formazan test to determine LC50.
|
Download PDF
|
|
K-562
|
5700 nM
|
MTT-formazan test to determine LC50.
|
Download PDF
|
|
SMMC-7721
|
0.63 mM
|
MTT assay
|
PMC9033422
|
|
LO2
|
0.43 mM
|
MTT assay
|
PMC9033422
|
|
CII cell line
|
~100 nM
|
Cell Titer Blue assay
|
Download PDF
|
|
MEC-1 cell line
|
~150 nM
|
Cell Titer Blue assay
|
Download PDF
|
|
HL-60/ara-C10
|
6900 nM
|
XTT assay, constructing growth curves
|
Download PDF
|
|
HL-60/CAFdA4
|
> 1000 nM
|
XTT assay, constructing growth curves
|
Download PDF
|
|
HL-60/CAFdA30
|
> 1000 nM
|
XTT assay, constructing growth curves
|
Download PDF
|
|
HUVEC
|
300 µM
|
MTT assay
|
Download PDF
|
|
MOLT-4
|
18 µM
|
MTT assay
|
Download PDF
|
|
CFPAC
|
>1000 µM
|
MTT assay
|
Download PDF
|
|
HeLa
|
>1000 µM
|
MTT assay
|
Download PDF
|
|
Kasumi-1
|
0.4 µM
|
AlamarBlue reagent, measured by fluorometer.
|
Download PDF
|
|
AML 8227 (bulk cells, CD15+ mature blast, CD34+CD38- LSC-enriched fraction)
|
LC50: bulk cells = 16.89 nM, CD15+ = 12.31 nM, CD34+CD38- =
|
Concentration effect curve graph and calculation using Prism version 6.00 software after 6 days of treatment and viability assessment.
|
Download PDF
|
|
CD34+CD38−KG1α cells
|
24 h: >106 nM; 48 h: 435.82 ± 51.23 nM; 72 h: 334.27 ± 28.76
|
CCK-8 assay
|
Download PDF
|
|
CD34+CD38−Kasumi cells
|
24 h: 7920.75 ± 5131.77 nM; 48 h: 476.32 ± 29.21 nM; 72 h: 1
|
CCK-8 assay
|
Download PDF
|
|
SKM-1
|
1.72 mM
|
MTS proliferation assay, calculated by Prism Graphpad software.
|
PMC6395322
|
|
MLLPTD/WT/RUNX1-S291fs cells
|
0.17 mM
|
MTS proliferation assay, calculated by Prism Graphpad software.
|
PMC6395322
|
|
CMK
|
70 ± 30 nM
|
CellTiter-Glo® Luminescent Cell Viability Assay
|
Download PDF
|
|
CMY
|
1795 ± 391 nM
|
CellTiter-Glo® Luminescent Cell Viability Assay
|
Download PDF
|
|
CMS
|
154 ± 21 nM
|
CellTiter-Glo® Luminescent Cell Viability Assay
|
Download PDF
|
|
M-07e
|
24 ± 4.4 nM
|
CellTiter-Glo® Luminescent Cell Viability Assay
|
Download PDF
|
|
AML-193
|
414 ± 29.9 nM
|
CellTiter-Glo® Luminescent Cell Viability Assay
|
Download PDF
|
|
NB4
|
123 ± 114 nM
|
CellTiter-Glo® Luminescent Cell Viability Assay
|
Download PDF
|
|
KG-1a
|
177 ± 43 nM
|
CellTiter-Glo® Luminescent Cell Viability Assay
|
Download PDF
|
|
TF-1
|
75 ± 52 nM
|
CellTiter-Glo® Luminescent Cell Viability Assay
|
Download PDF
|
|
HL60R
|
47.87±4.02 μg/ml
|
Cell number counting using Trypan-blue assay
|
Download PDF
|
|
AML-NS8 cells
|
133 nM
|
assay, sigmoidal interpolation curve
|
Download PDF
|
|
51D1 (Rad51D-deficient CHO cells) and 51D1.3 (Rad51D-complemented CHO cells)
|
~0.3 µmol/L
|
Clonogenic survival assay, calculated using GraphPad Prism5 software based on survival curves.
|
PMC3777512
|
|
irs1SF (XRCC3-deficient CHO cells) and AA8 (wild-type CHO cells)
|
0.4–0.5 µmol/L
|
Clonogenic survival assay, calculated using GraphPad Prism5 software based on survival curves.
|
PMC3777512
|
|
AML adult
|
0.44 μg/ml
|
MTT assay, LC50 measurement
|
PMC3687416
|
|
L1210
|
0.051 µM
|
MTT test for cell viability
|
PMC3367491
|
|
L1210
|
0.022 µM
|
MTT test for cell viability
|
PMC3367491
|
|
L1210R
|
71.7 µM
|
MTT test for cell viability
|
PMC3367491
|
|
L1210R
|
48.2 µM
|
MTT test for cell viability
|
PMC3367491
|
|
MCF-7
|
>100 µM
|
MTT test for cell viability
|
PMC3367491
|
|
MCF-7
|
>100 µM
|
MTT test for cell viability
|
PMC3367491
|
